References
- Khalil J, Bensaid B, Elkacemi H, et al. Venous thromboembolism in cancer patients: an underestimated major health problem. World J Surg Oncol [Internet]. 2015;13:204. [cited 2 Feb 2016]. Available from: http://www.wjso.com/content/13/1/204.
- Cote DJ, Smith TR. Venous thromboembolism in brain tumor patients. J Clin Neurosci [Internet]. 2015;25:13–18. [cited 1 Dec 2015]. Available from: http://linkinghub.elsevier.com/retrieve/pii/S096758681500497X.
- Stein PD, Beemath A, Meyers FA, et al. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med. 2006;119:60–68.
- Petterson TM, Marks RS, Ashrani AA, et al. Risk of site-specific cancer in incident venous thromboembolism: a population-based study. Thromb Res [Internet]. 2015;135(3):472–478. Available from: http://www.sciencedirect.com/science/article/pii/S0049384814006793.
- Semrad TJ, O’Donnell R, Wun T, et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg. 2007;106(4):601–608.
- Sawaya R, Zuccarello M, Elkalliny M, et al. Postoperative venous thromboembolism and brain tumors: Part I. Clinical profile. J Neurooncol [Internet]. 1992;14(2):119–125. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1331348.
- Pan E, Tsai JS, Mitchell SB. Retrospective study of venous thromboembolic and intracerebral hemorrhagic events in glioblastoma patients. Anticancer Res. 2009;29:4309–4313.
- Simanek R, Vormittag R, Hassler M, et al. Venous thromboembolism and survival in patients with high-grade glioma. Neuro Oncol. 2007;9(2):89–95.
- Brandes AA, Scelzi E, Salmistraro G, et al. Incidence and risk of thromboembolism during treatment of high-grade gliomas: a prospective study. Eur J Cancer [Internet]. 1997;33(10):1592–1596. [cited 7 Dec 2015]. Available from: http://www.ejcancer.com/article/S0959-8049%2897%2900167-6/abstract.
- Smith TR, Lall RR, Graham RB, et al. Venous thromboembolism in high grade glioma among surgical patients: results from a single center over a 10 year period. J Neurooncol [Internet]. 2014;120(2):347–352. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25062669.
- Smith TR, Nanney AD, Lall RR, et al. Development of venous thromboembolism (VTE) in patients undergoing surgery for brain tumors: results from a single center over a 10year period. J Clin Neurosci [Internet]. 2015;22(3):519–525. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0967586814006092.
- Seidel C, Hentschel B, Simon M, et al. A comprehensive analysis of vascular complications in 3,889 glioma patients from the German glioma network. J Neurol [Internet]. 2013;260(3):847–855. Available from: http://link.springer.com/10.1007/s00415-012-6718-9.
- Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med [Internet]. 2006;166(4):458–464. Available from: http://archinte.jamanetwork.com/article.aspx?articleid=409843.
- Næss IA, Christiansen SC, Romundstad P, et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost [Internet]. 2007;5(4):692–699. Available from: http://doi.wiley.com/10.1111/j.1538-7836.2007.02450.x.
- Zwicker JI, Furie BC, Furie B. Cancer-associated thrombosis. Crit Rev Oncol Hematol [Internet]. 2007;62(2):126–136. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1040842807000108.
- Falanga A, Russo L, Verzeroli C. Mechanisms of thrombosis in cancer. Thromb Res [Internet]. 2013;131:S59–S62. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0049384813700240.
- Milsom C, Rak J. Tissue factor and cancer. Pathophysiol Haemost Thromb [Internet]. 2007;36(3–4):160–176. Available from: http://www.karger.com/doi/10.1159/000175154.
- Sartori MT, Della Puppa A, Ballin A, et al. Prothrombotic state in glioblastoma multiforme: an evaluation of the procoagulant activity of circulating microparticles. J Neurooncol [Internet]. 2011;104(1):225–231. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21104297.
- Hamada K, Kuratsu J, Saitoh Y, et al. Expression of tissue factor correlates with grade of malignancy in human glioma. Cancer [Internet]. 1996;77(9):1877–1883. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8646688.
- Khorana AA, Francis CW, Menzies KE, et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost [Internet]. 2008;6(11):1983–1985. Available from: http://doi.wiley.com/10.1111/j.1538-7836.2008.03156.x.
- Zhang Y, Deng Y, Luther T, et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest [Internet]. 1994;94(3):1320–1327. Available from: http://www.jci.org/articles/view/117451.
- Mechtcheriakova D, Wlachos A, Holzmuller H, et al. Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1. Blood. 1999;93(11):3811–3823.
- Rong Y, Belozerov VE, Tucker-Burden C, et al. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Cancer Res [Internet]. 2009;69(6):2540–2549. Available from: http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.CAN-08-1547.
- Daumas-Duport C, Scheithauer B, O’Fallon J, et al. Grading of astrocytomas. A simple and reproducible method. Cancer [Internet]. 1988;62(10):2152–2165. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3179928.
- Brat DJ, Van Meir EG. Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Investig [Internet]. 2004;84(4):397–405. Available from: http://www.nature.com/doifinder/10.1038/labinvest.3700070.
- Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol [Internet]. 2007;114(2):97–109. Available from: http://link.springer.com/10.1007/s00401-007-0243-4.
- Aharon A, Brenner B. Microparticles, thrombosis and cancer. Best Pract Res Clin Haematol. 2009;22(1):61–69. doi:10.1016/j.beha.2008.11.002.
- Franchini M, Montagnana M, Targher G, et al. Pathogenesis, clinical and laboratory aspects of thrombosis in cancer. J Thromb Thrombolysis [Internet]. 2007;24(1):29–38. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17396228.
- Ogiichi T, Hirashima Y, Nakamura S, et al. Tissue factor and cancer procoagulant expressed by glioma cells participate in their thrombin-mediated proliferation. J Neurooncol [Internet]. 2000;46(1):1–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10896200.
- Altschuler E, Moosa H, Selker RG, et al. The risk and efficacy of anticoagulant therapy in the treatment of thromboembolic complications in patients with primary malignant brain tumors. Neurosurgery [Internet]. 1990;27(1):74–76; discussion 77. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2377284.
- Levin JM, Schiff D, Loeffler JS, et al. Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology [Internet]. 1993;43(6):1111–1114. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8170553.
- Ruff RL, Posner JB. Incidence and treatment of peripheral venous thrombosis in patients with glioma. Ann Neurol [Internet]. 1983;13(3):334–336. Available from: http://www.ncbi.nlm.nih.gov/pubmed/6303201.
- Choucair AK, Silver P, Levin VA. Risk of intracranial hemorrhage in glioma patients receiving anticoagulant therapy for venous thromboembolism. J Neurosurg [Internet]. 1987;66(3):357–358. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3819830.
- Jo JT, Schiff D, Perry JR. Thrombosis in brain tumors. Semin Thromb Hemost. 2014;40(03):325–331.
- Lyman GH, Bohlke K, Khorana AA, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American society of clinical oncology clinical practice guideline update 2014. J Clin Oncol. 2015;33(6):654–656.
- Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline. Chest [Internet]. 2016;149:315–352. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0012369215003359.
- Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: CHEST guideline. Chest [Internet]. 2012;141(2):e195S–e226S. Available from: http://linkinghub.elsevier.com/retrieve/pii/S001236921260124X.
- Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med [Internet]. 2003;349(2):146–153. Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa025313.
- Akl EA, Kahale L, Barba M, et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev [Internet]. 2014;7(7):CD006650. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25004410.
- Akl EA, Kahale L, Neumann I, et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev [Internet]. 2014;6(6):CD006649. Available from: http://doi.wiley.com/10.1002/14651858.CD006649.pub6.
- Easaw JC, Shea-Budgell MA, Wu CMJ, et al. Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 2: treatment. Curr Oncol [Internet]. 2015;22(2):144. Available from: http://www.current-oncology.com/index.php/oncology/article/view/2587.
- Drappatz J. Medical care of patients with brain tumors. Contin Lifelong Learn Neurol [Internet]. 2012;18(2):275–294. Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed10&NEWS=N&AN=2012209968.
- PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d’Embolie Pulmonaire par Interruption Cave) randomized study. Circulation [Internet]. 2005;112(3):416–422. Available from: http://circ.ahajournals.org/cgi/doi/10.1161/CIRCULATIONAHA.104.512834.
- US Food and Drug Administration. Inferior vena cava (IVC) filters: initial communication: risk of adverse events with long term use. Safety Alerts for Human Medical Products [Internet]. 2013. [cited 22 Jan 2016]. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm221707.htm.
- Mismetti P, Laporte S, Pellerin O, et al. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism. JAMA [Internet]. 2015;313(16):1627. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2015.3780.
- Van Doormaal FF, Raskob GE, Davidson BL, et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thromb Haemost [Internet]. 2009;101(4):762–769. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19350123.
- Cohen AT, Spiro TE, Büller HR, et al. Rivaroxaban for thromboprophylaxis in acutely Ill medical patients. N Engl J Med [Internet]. 2013;368(6):513–523. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa1111096.
- Levine MN, Gu C, Liebman HA, et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost [Internet]. 2012;10(5):807–814. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22409262.
- Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood. 2012;119(13):3016–3023.
- Khorana AA, Carrier M, Garcia DA, et al. Guidance for the prevention and treatment of cancer-associated venous thromboembolism. J Thromb Thrombolysis [Internet]. 2016;41(1):81–91. Available from: http://link.springer.com/10.1007/s11239-015-1312-5.
- Easaw JC, Shea-Budgell MA, Wu CMJ, et al. Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 1: prophylaxis. Curr Oncol [Internet]. 2015;22(2):133. Available from: http://www.current-oncology.com/index.php/oncology/article/download/2587/1732\nhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed13&NEWS=N&AN=2015967614.
- Carrier M, Khorana AA, Moretto P, et al. Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer. Am J Med [Internet]. 2014;127(1):82–86.e1. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24384102\nhttp://linkinghub.elsevier.com/retrieve/pii/S0002934313008383.
- Kanaan AO, Silva MA, Jl D, et al. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients. Clin Ther [Internet]. 2007;29(11):2395–2405. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0149291807003645.
- Carrier M, Cameron C, Delluc A, et al. Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis. Thromb Res. 2014;134(6):1214–1219. doi:10.1016/j.thromres.2014.09.039.
- Eppsteiner RW, Shin JJ, Johnson J, et al. Mechanical compression versus subcutaneous heparin therapy in postoperative and posttrauma patients: a systematic review and meta-analysis. World J Surg [Internet]. 2010;34(1):10–19. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20020289.
- Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: pulmonary embolism prevention (PEP) trial. Lancet (London, England) [Internet]. 2000;355(9212):1295–1302. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10776741.
- Perry JR, Julian JA, Laperriere NJ, et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost [Internet]. 2010;8(9):1959–1965. Available from: http://doi.wiley.com/10.1111/j.1538-7836.2010.03973.x.
- Chan AT, Atiemo A, Diran LK, et al. Venous thromboembolism occurs frequently in patients undergoing brain tumor surgery despite prophylaxis. J Thromb Thrombolysis [Internet]. 1999;8(2):139–142. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10436144.
- Collen JF, Jackson JL, Shorr AF, et al. Prevention of venous thromboembolism in neurosurgery: a metaanalysis. Chest [Internet]. 2008;134(2):237–249. Available from: http://www-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/books/PMH0025970/.
- Iorio A, Agnelli G. Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. Arch Intern Med [Internet]. 2000;160(15):2327–2332. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10927730.
- Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: CHEST guideline. Chest [Internet]. 2012;141(2):e227S–e277S. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0012369212601251.
- Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy. Antithrombotic therapy and prevention of thrombosis, 9th ed: american College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl.):e326S–e350S.
- Spyropoulos AC, Douketis JD, Dc W. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood. 2012;120(15):2954–2962.
- Casaubon LK, Boulanger J-M, Blacquiere D, et al. Canadian stroke best practice recommendations : hyperacute stroke care guidelines, update 2015. Int J Stroke [Internet]. 2015;10(6):924–940. Available from: http://doi.wiley.com/10.1111/ijs.12551.
- Robinson AA, Ikuta K, Soverow J. Anticoagulation for the acute management of ischemic stroke. Yale J Biol Med. 2014;87(2):199–206.
- Schiff D, Lee EQ, Nayak L, et al. Medical management of brain tumors and the sequelae of treatment. Neuro Oncol [Internet]. 2015;17(4):488–504. Available from: http://neuro-oncology.oxfordjournals.org/content/17/4/488.long.
- Carrier M, Khorana AA, Zwicker JI, et al. Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH. J Thromb Haemost [Internet]. 2013;11(9):1760–1765. Available from: http://doi.wiley.com/10.1111/jth.12338.
- Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA [Internet]. 2008;300(19):2277–2285. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19017914.
- Hurwitz HI, Saltz LB, Van Cutsem E, et al. Venous thromboembolic events with chemotherapy plus bevacizumab: A pooled analysis of patients in randomized phase II and III studies. J Clin Oncol. 2011;29(13):1757–1764.
- Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med [Internet]. 2014;370(8):699–708. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24552317.
- Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med [Internet]. 2014;370(8):709–722. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24552318.
- Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99(16):1232–1239.
- Fraum TJ, Kreisl TN, Sul J, et al. Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy. J Neurooncol [Internet]. 2011;105(2):281–289. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1286457911001985.
- Hapani S, Sher A, Chu D, et al. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology [Internet]. 2010;79(1–2):27–38. Available from: http://www.karger.com/doi/10.1159/000314980.
- Norden AD, Bartolomeo J, Tanaka S, et al. Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients. J Neurooncol. 2012;106(1):121–125.
- Kreisl TN, Toothaker T, Karimi S, et al. Ischemic stroke in patients with primary brain tumors. Neurology [Internet]. 2008;70(24):2314–2320. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18541885.
- Jauch EC, Saver JL, Adams HP, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American heart association/American stroke association. Stroke [Internet]. 2013;44(3):870–947. Available from: http://stroke.ahajournals.org/cgi/doi/10.1161/STR.0b013e318284056a.
- Lin E, Rosenthal MA, Le BH, et al. Neuro-oncology and palliative care: a challenging interface. Neuro Oncol [Internet]. 2012;14(Suppl 4):iv3–iv7. Available from: http://neuro-oncology.oxfordjournals.org/cgi/doi/10.1093/neuonc/nos209.
- Sheard L, Prout H, Dowding D, et al. The ethical decisions UK doctors make regarding advanced cancer patients at the end of life - the perceived (in) appropriateness of anticoagulation for venous thromboembolism: a qualitative study. BMC Med Ethics [Internet]. 2012;13(1):22. Available from: http://www.biomedcentral.com/1472-6939/13/22.
- Soto-Cardenas M, Pelayo-Garcia G, Rodriguez-Camacho A, et al. Venous thromboembolism in patients with advanced cancer under palliative care: additional risk factors, primary/secondary prophylaxis and complications observed under normal clinical practice. Palliat Med [Internet]. 2008;22(8):965–968. Available from: http://pmj.sagepub.com/cgi/doi/10.1177/0269216308098803.
- Kirkova J, Fainsinger RL. Thrombosis and anticoagulation in palliative care: an evolving clinical challenge. J Palliat Care [Internet]. 2004;20(2):101–104. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15332474.
- Tran QNH. Review article: role of palliative low-molecular-weight heparin for treating venous thromboembolism in patients with advanced cancer. Am J Hosp Palliat Med [Internet]. 2010;27(6):416–419. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20197558.
- Noble SIR, Shelley MD, Coles B, et al. Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis. Lancet Oncol [Internet]. 2008;9(6):577–584. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18510989.
- Weber C, Merminod T, Herrmann FR, et al. Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study. Support Care Cancer [Internet]. 2008;16(7):847–852. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17940809.
- McLean S, Ryan K, O’Donnell JS. Primary thromboprophylaxis in the palliative care setting: a qualitative systematic review. Palliat Med. 2010;24(4):386–395.
- Johnson MJ, Sproule MW, Paul J. The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer. Clin Oncol (R Coll Radiol) [Internet]. 1999;11(2):105–110. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10378636.
- Noble SIR, Finlay IG. Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study. Palliat Med [Internet]. 2005;19(3):197–201. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15920933.
- Noble S. The challenges of managing cancer related venous thromboembolism in the palliative care setting. Postgrad Med J [Internet]. 2007;83(985):671–674. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2659959&tool=pmcentrez&rendertype=abstract.